MediciNova
MNOV
MediciNova (MNOV) news
Recent news
Medicinova - patent expected to expire no earlier than September 2042
AInvest Wire · Jun 8, 2026MediciNova spikes 18% after announcing abstract regarding MN-166 (ibudilast) in chlorine gas-induced lung injury accepted for presentation at the 63rd annual meeting of the Society of Toxicology
MediciNova spikes 18% after announcing abstract regarding MN-166 (ibudilast) in chlorine gas-induced lung injury accepted for presentation at the 63rd annual meeting of the Society of Toxicology MediciNova, a biopharmaceutical company, recently announced that an abstract regarding the results of a…
AInvest Wire · Dec 22, 2023ImportantMediciNova surges 20% premarket after announcing new data and results of a Phase 2 clinical trial of MN-166 (ibudilast)
AInvest Wire · Nov 20, 2023MediciNova announces new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma presented at the 28th annual meeting of the Society for Neuro-Oncology
AInvest Wire · Nov 19, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.